WO2021247916A8 - Azetidine and spiroazetidine compounds and uses thereof - Google Patents

Azetidine and spiroazetidine compounds and uses thereof Download PDF

Info

Publication number
WO2021247916A8
WO2021247916A8 PCT/US2021/035771 US2021035771W WO2021247916A8 WO 2021247916 A8 WO2021247916 A8 WO 2021247916A8 US 2021035771 W US2021035771 W US 2021035771W WO 2021247916 A8 WO2021247916 A8 WO 2021247916A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
spiroazetidine
azetidine
neurological disorders
alone
Prior art date
Application number
PCT/US2021/035771
Other languages
French (fr)
Other versions
WO2021247916A1 (en
Inventor
Iwona WRONA
Kerem OZBOYA
Bertrand Le Bourdonnec
Madeline MACDONNELL
Vanessa KURIA
Matthew Lucas
Mitch RIVERS
Byron Delabarre
Original Assignee
Yumanity Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yumanity Therapeutics, Inc. filed Critical Yumanity Therapeutics, Inc.
Publication of WO2021247916A1 publication Critical patent/WO2021247916A1/en
Publication of WO2021247916A8 publication Critical patent/WO2021247916A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
PCT/US2021/035771 2020-06-03 2021-06-03 Azetidine and spiroazetidine compounds and uses thereof WO2021247916A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063034077P 2020-06-03 2020-06-03
US63/034,077 2020-06-03
US202063117882P 2020-11-24 2020-11-24
US63/117,882 2020-11-24

Publications (2)

Publication Number Publication Date
WO2021247916A1 WO2021247916A1 (en) 2021-12-09
WO2021247916A8 true WO2021247916A8 (en) 2022-01-27

Family

ID=78829946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/035771 WO2021247916A1 (en) 2020-06-03 2021-06-03 Azetidine and spiroazetidine compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2021247916A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023107547A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Azetidine and spiroazetidine compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015040A1 (en) * 2008-08-07 2010-02-11 Powmri Ltd Therapy and prevention of tdp-43 proteinopathy
HUE028394T2 (en) * 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidine compound
EP3400211A1 (en) * 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US20180320179A1 (en) * 2017-05-02 2018-11-08 Dow Agrosciences Llc Lanosterol 14-alpha demethylase (cyp51) nucleic acid molecules that control pathogens
WO2019246494A1 (en) * 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders

Also Published As

Publication number Publication date
WO2021247916A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
WO2019209962A8 (en) Compounds and uses thereof
WO2005012294A8 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
IL188789A0 (en) Formulation and method for administration of ophthalmologically active agents
MX2020009942A (en) Compounds and uses thereof.
MX2021011488A (en) Compounds and uses thereof.
IL214607A0 (en) 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
IL225192A (en) Combination of dextromethorphan and quinidine for use in the treatment of mental illness, neuropathic pain or brain injury
EP2116245A3 (en) EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
MX2019008124A (en) Methods for the treatment of neurological disorders.
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
WO2006031720A3 (en) D-methionine formulation with improved biopharmaceutical properties
WO2020154571A8 (en) Compounds and uses thereof
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
WO2021247916A8 (en) Azetidine and spiroazetidine compounds and uses thereof
WO2019209948A8 (en) Compounds and uses thereof
WO2022063869A3 (en) Compounds for the treatment of viral infections
EA202192047A1 (en) COMPOUNDS AND THEIR APPLICATIONS
WO2023107547A3 (en) Azetidine and spiroazetidine compounds and uses thereof
WO2005002522A3 (en) Compositions and methods for treating tissue ischemia
WO2023107597A3 (en) Bicyclic heteroaromatic amide compounds and uses thereof
WO2023107552A3 (en) Purines and methods of their use
WO2021247921A8 (en) Benzothiazole compounds and uses thereof
WO2022051029A3 (en) Methods for the prevention and treatment of hearing loss
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21818922

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21818922

Country of ref document: EP

Kind code of ref document: A1